市場調查報告書
商品編碼
1172560
全球頭頸癌治療市場:市場規模、市場份額、趨勢分析、機遇和預測:按類型、治療類型、給藥途徑、最終用戶、地區2018-2028Head and Neck Cancer Therapeutics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2018-2028, Segmented By Type ; Treatment Type ; Route of Administration ; By End-User ; Region |
全球頭頸癌治療市場規模預計將從 2021 年的 11 億美元增長到 2028 年的約 26 億美元,在預測期內以 12.6% 的複合年增長率增長。 生物仿製藥的使用增加、早期診斷和積極的醫療改革正在推動市場增長。
本報告研究了全球頭頸癌治療市場,並提供了全面的信息,包括市場概況、市場分析和公司概況。
注:對於最終交付成果,除上述公司外的其他公司的財務信息將在數據可用時提供。
在最終可交付成果中,細分和公司可能會隨著詳細的補充信息而發生變化。
Global Head and Neck Cancer Therapeutics Market is growing at a high CAGR because of the rising use of biosimilars and early diagnostic methods as well as positive healthcare reforms.
A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Head and Neck Cancer Therapeutics Market was worth USD 1.1 billion in the year 2021. The market is projected to grow at a CAGR of 12.6% from 2022-2028 (forecast period), earning revenues of around USD 2.6 billion by the end of 2028. The Global Head and Neck Cancer Therapeutics Market is booming because of the rising demand for consumer electronic items like smartphones, televisions, and digital cameras, as well as the increased manufacturing of electric cars. In addition, rising demand for IoT devices is emerging as a significant driver of market expansion. However, high dependence on other countries for semiconductor chip imports may act as a huge restraining factor for market growth.
Increases in the prevalence of specific diseases and the availability of better healthcare thanks to public and private sector initiatives are all expected to propel the industry forward in the next years. The global market for head and neck cancer treatments is growing as a result of several factors, including the rising incidence of this disease worldwide, the rising preference for multimodal approaches to care, and the rising emphasis on research and development to identify the most effective clinical therapy.
In addition, an increase in risk factors such as alcohol, cigarette smoking, and tobacco use is anticipated to contribute to the growing worldwide need for head and neck cancer treatments.
Market growth is anticipated to be stymied by the high expenses associated with the treatment plan, the unfavorable reactions of alternative treatment alternatives, the dearth of insurance services, and the inadequate healthcare system in low- and middle-income countries. Moreover, this patient population faces major issues, such as morbidity and bad quality of life, as a direct result of the incapacitating impact of normal healthcare practices.
On the basis of end-user segmentation, the Global Head and Neck Cancer Therapeutics Market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. Whereby hospitals and specialty clinics take a sizable amount in market share. Due to simple access to medications and inexpensive distribution costs, producers are very likely to distribute their goods, which explains the dominance. According to the Drug Channels Institute's research, the top five specialty pharmacies in the globe in 2021 were Humana specialty pharmacy, Accredo, CVS Specialty, Walgreens stores, and Optum specialty pharmacy.
The global market for head and neck cancer therapies is divided into five primary regions based on geographical presence. These regions are North America, Europe, The Asia Pacific, Latin America, the Middle East, and Africa. The high frequency of HPV-induced malignancies and the high smoking rate in North America will continue to provide the region with a dominant position in the worldwide head and neck cancer treatment market. It is anticipated that Europe will hold the second biggest market share in the global market for head and neck cancer therapies.
The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) that produced the 2019 coronavirus disease (COVID-19) pandemic poses a unique challenge to the world's healthcare infrastructure, including the Global Head and Neck Cancer Therapeutics Market. Standardized treatment for cancer patients was a part of this difficulty. During this time, most in-hospital cancer treatments were discontinued, and only select patients were given radiation therapy with the goal of curing them in accordance with strict protocols to ensure their safety, thereby leading to disturbances and inconveniences in the Global Head and Neck Cancer Therapeutics Market.
Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Ltd., GlaxoSmithKline PLC, Novartis International AG, Sanofi, Bayer AG, Hoffmann-LA Roche AG, Merck & co., INC., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., and Other Prominent Players are active in this industry. AstraZeneca and Pfizer are expected to benefit from the approval of Imfinzi and Bavencio during the projection period. Sanofi and Eli Lilly have been affected by expiring patents and biosimilar medicine competition. Several market participants are expected to collaborate on meeting unmet requirements, discovering novel targets, and developing stronger treatment pipelines.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Head and Neck Cancer Therapeutics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Head and Neck Cancer Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Note: Financial in information in case of non-listed companies will be provided as per availability
The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable